Brighton Jones’s Cardiff Oncology CRDF Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$20.3K Sell
16,741
-3,712
-18% -$3.98K ﹤0.01% 1381
2026
Q2
$26.6K Buy
20,453
+3,497
+21% +$5.55K ﹤0.01% 1392
2026
Q1
$27.5K Buy
+16,956
New +$34.8K ﹤0.01% 1182
2025
Q4
– Sell
-16,506
Closed -$34K – 234
2025
Q3
$34K Buy
16,506
+3
+0% +$8 ﹤0.01% 1013
2025
Q2
$52K Buy
16,503
+3
+0% +$9 ﹤0.01% 905
2025
Q1
$51.8K Buy
+16,500
New +$65.2K ﹤0.01% 689

Other funds holding CRDF

Brighton Jones's CRDF Position: Q3 2026 in Review

Brighton Jones reduced its Cardiff Oncology (CRDF) stake by 18% in Q3 2026, selling an estimated $3.98K and leaving 16,741 shares worth $20.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1381.

Brighton Jones first reported a position in CRDF in Q1 2025 and has held it in 6 quarters since. The position peaked at $52K in Q2 2025. 66 funds tracked by Wall St. Rank hold CRDF as of Q3 2026.

  • Brighton Jones held 16,741 shares of Cardiff Oncology worth $20.3K as of Q3 2026.
  • Brighton Jones sold 3,712 Cardiff Oncology shares in Q3 2026, an estimated $3.98K.
  • Cardiff Oncology made up ﹤0.01% of Brighton Jones's portfolio in Q3 2026, its #1381 holding.
  • Brighton Jones first reported a position in Cardiff Oncology in Q1 2025 and has held it in 6 quarters since.
  • Brighton Jones's Cardiff Oncology position peaked at $52K in Q2 2025.
  • 66 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2026.

Based on Brighton Jones's 13F filing for Q3 2026, filed 3 Nov 2026.